Aimable Nahimana

Dr. Aimable Nahimana

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CBCaroline S Breton
Caroline S Breton
ANAimable Nahimana
Aimable Nahimana
DADominique Aubry
Dominique Aubry
JMJulie Macoin
Julie Macoin
PMPierre Moretti
Pierre Moretti
JBJonathan Back
Jonathan Back
CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb), GBR 401, and investigate its therapeutic potential on human B cell malignancies.

17 January 2014 in Autophagy
Verified
Journal Article
Open access
VGVanessa Ginet
Vanessa Ginet
JPJulien Puyal
Julien Puyal
CRCoralie Rummel
Coralie Rummel
DADominique Aubry
Dominique Aubry
CBCaroline Breton
Caroline Breton
ANAimable Nahimana
Aimable Nahimana
APO866, an inhibitor of NAD biosynthesis, exhibits potent antitumor properties in various malignancies. Recently, it has been shown that APO866 induces apoptosis and autophagy in human hematological cancer cells, but the role of autophagy in APO866-induced cell death remains unclear. Here, we report studies on the molecular mechanisms underlying APO866-induced cell death with emphasis on autophagy. Treatment of leukemia and lymphoma cells with APO866 induced both autophagy, as evidenced by an increase in autophagosome formation and in SQSTM1/p62 degradation, but also increased caspase activation as revealed by CASP3/caspase 3 cleavage. As an underlying mechanism, APO866-mediated autophagy was found to deplete CAT/catalase, a reactive oxygen species (ROS) scavenger, thus promoting ROS production and cell death. Inhibition of autophagy by ATG5 or ATG7 silencing prevented CAT degradation, ROS production, caspase activation, and APO866-induced cell death. Finally, supplementation with exogenous CAT also abolished APO866 cytotoxic activity. Altogether, our results indicated that autophagy is essential for APO866 cytotoxic activity on cells from hematological malignancies and also indicate an autophagy-dependent CAT degradation, a novel mechanism for APO866-mediated cell killing. Autophagy-modulating approaches could be a new way to enhance the antitumor activity of APO866 and related agents.

10 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MGMoustafa Ghanem
Moustafa Ghanem
Irene CaffaIrene Caffa
Irene Caffa
ARAlberto Del Rio
Alberto Del Rio
JFJorge Franco
Jorge Franco
MPMarco Daniele Parenti
Marco Daniele Parenti
FPFrancesco Piacente
Francesco Piacente
Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer activity in clinical trials raised the possibility that cancer cells may also exploit alternative NAD-producing enzymes. Recent studies show the relevance of nicotinic acid phosphoribosyltransferase (NAPRT), the rate-limiting enzyme of the Preiss–Handler NAD-production pathway for a large group of human cancers. We demonstrated that the NAPRT inhibitor 2-hydroxynicotinic acid (2-HNA) cooperates with the NAMPT inhibitor FK866 in killing NAPRT-proficient cancer cells that were otherwise insensitive to FK866 alone. Despite this emerging relevance of NAPRT as a potential target in cancer therapy, very few NAPRT inhibitors exist. Starting from a high-throughput virtual screening approach, we were able to identify and annotate two additional chemical scaffolds that function as NAPRT inhibitors. These compounds show comparable anti-cancer activity to 2-HNA and improved predicted aqueous solubility, in addition to demonstrating favorable drug-like profiles.

19 November 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
ACAnne-Julie Cloux
Anne-Julie Cloux
DADominique Aubry
Dominique Aubry
MHMathieu Heulot
Mathieu Heulot
CWChristian Widmann
Christian Widmann
OEOussama ElMokh
Oussama ElMokh
ANAimable Nahimana
Aimable Nahimana
Oncotarget | https://doi.org/10.18632/oncotarget.27336 Anne-Julie Cloux, Dominique Aubry, Mathieu Heulot, Christian Widmann, Oussama ElMokh, Francesco Piacente, Michele Cea, Alessio Nencioni, Axel Bellotti,...

8 April 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
OEOussama ElMokh
Oussama ElMokh
SMSaki Matsumoto
Saki Matsumoto
PBPaulina Biniecka
Paulina Biniecka
ABAxel Bellotti
Axel Bellotti
KSKarin Schaeuble
Karin Schaeuble
MDMichel A. Duchosal
Michel A. Duchosal
Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD+) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD+ biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in preclinical studies but failed in clinical ones. To identify parameters that could negatively affect the therapeutic efficacy of NAMPT inhibitors and propose therapeutic strategies to circumvent such failure, we performed metabolomics analyses in tumor environment and explored the effect of the interaction between microbiota and cancer cells. Here we show that tumor environment enriched in vitamin B3 (NAM) or nicotinic acid (NA) significantly lowers the anti-tumor efficacy of APO866, a prototypic NAMPT inhibitor. Additionally, bacteria (from the gut, or in the medium) can convert NAM into NA and thus fuel an alternative NAD synthesis pathway through NA. This leads to the rescue from NAD depletion, prevents reactive oxygen species production, preserves mitochondrial integrity, blunts ATP depletion, and protects cancer cells from death.Our data in an in vivo preclinical model reveal that antibiotic therapy down-modulating gut microbiota can restore the anti-cancer efficacy of APO866. Alternatively, NAphosphoribosyltransferase inhibition may restore anti-cancer activity of NAMPT inhibitors in the presence of gut microbiota and of NAM in the diet.

1 September 2015 in Biochimie
Verified
Journal Article
Closed access
CBCaroline S. Breton
Caroline S. Breton
DADominique Aubry
Dominique Aubry
VGVanessa Ginet
Vanessa Ginet
JPJulien Puyal
Julien Puyal
MHMathieu Heulot
Mathieu Heulot
ANAimable Nahimana
Aimable Nahimana